Delivery of a Medicinal Product Containing Tender - 143665818

Procurement Summary

Country: Poland

Summary: Delivery of a Medicinal Product Containing the Active Substance Belantamab Mafodotin Covered by Reimbursement under the B.54 Drug Program for the Treatment of Patients with Multiple Myeloma

Deadline: 29 Jun 2026

Posting Date: 20 Jun 2026

Other Information

Notice Type: Tender

TOT Ref.No.: 143665818

Document Ref. No.: 2026/BZP 00299759/01

Competition: ICB

Financier: Self Financed

Purchaser Ownership: Public

Tender Value: Refer Document

CPV Classification

33600000 - Pharmaceutical products

Purchaser's Detail

Name: Login to see tender_details

Address: Login to see tender_details

Email: Login to see tender_detailsLogin to see details

Tender Details

SECTION II - BASIC INFORMATION 2.1.) The announcement concerns: Public procurement 2.2.) The announcement concerns social services and other specific services: No 2.3.) Name of the order or framework agreement: Supply of a medicinal product containing the substance active Belantamab mafodotin covered by reimbursement under the B.54 drug program for the treatment of patients with multiple myeloma 2.4.) Procedure ID: ocds-148610-d34b2e6a-b38a-4ba2-88da-99bfb50f3f7c 2.5.) Announcement number: 2026/BZP 00299759 2.6.) Version announcements: 01 2.7.) Announcement date: 2026-06-19 2.8.) The order or framework agreement was included in the procedure plan: Yes 2.9.) BZP proceedings plan number: 2026/BZP 00019333/09/P 2.10.) Procedure plan item identifier: 2.2.8 35. Medicinal products reimbursed under the Drug Programs, Chemotherapy and Emergency Access to Drug Technologies 2.11.) Only contractors referred to in Art. 94 of the Act: No 2.14.) Whether the order or framework agreement applies project or program co-financed by the European Union: No 2.16.) Procedure for awarding the contract along with the legal basis The order is awarded in the basic mode on the basis of: Art. 275 point 1 of the Act
Category: Deliveries Date: 2026-06-19 2026-06-29 add to watchlist City: Lublin Description: Delivery of a medicinal product containing the active substance Belantamab mafodotin covered by reimbursement under the B.54 drug program for the treatment of myeloma patients plasmacytic

Documents

 Tender Notice